---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019624"
form_type: "8-K/A"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:20:58.858208+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Harmony files Zynerba FY2022 audited financials; net loss $35M, accumulated deficit $274.5M

## Summary
- Zynerba FY2022 net loss $35.0M ($0.82 loss per share); no revenue; R&D expense $21.1M, G&A $14.2M.
- Cash and equivalents $50.6M at Dec 31, 2022; sufficient to fund operations to mid-2024 per management.
- Acquisition closed Oct 10, 2023; pro forma combined statements filed as Exhibit 99.3 (not included in this text).
- Zynerba clinical-stage pipeline targets FXS and 22q deletion syndrome; deferred Phase 3 ASD program.

## SEC filing metadata
- accession: 0001558370-23-019624
- form_type: 8-K/A
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837023019624/0001558370-23-019624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837023019624/hrmy-20231010x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019624
- JSON: https://secwatch.observer/filing/0001558370-23-019624.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.